Optinose to Present at the Needham Virtual Healthcare Conference
12 avr. 2021 16h15 HE
|
Optinose, Inc.
YARDLEY, Pa., April 12, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Operational Highlights
03 mars 2021 07h00 HE
|
Optinose, Inc.
Company reports fourth quarter and full year 2020 XHANCE net revenue of $15.6 million and $48.4 million Full year 2020 XHANCE prescriptions increased 70% compared to full year 2019 Company...
Optinose Announces Reporting Date for Fourth Quarter 2020 Financial Results
17 févr. 2021 17h23 HE
|
Optinose, Inc.
Conference Call and Webcast to be held March 3, 2021 at 8:00 a.m. Eastern Time Company to Present at the Cowen 41st Annual Health Care Conference on March 4, 2021 YARDLEY, Pa., Feb. 17, 2021 ...
Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
25 janv. 2021 16h30 HE
|
Optinose, Inc.
YARDLEY, Pa., Jan. 25, 2021 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today...
Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
21 déc. 2020 10h00 HE
|
Optinose, Inc.
YARDLEY, Pa., Dec. 21, 2020 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today...
Optinose Announces Changes to Board of Directors
01 déc. 2020 16h30 HE
|
Optinose, Inc.
YARDLEY, Pa., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Reports Third Quarter 2020 Financial Results and Recent Operational Highlights
05 nov. 2020 07h00 HE
|
Optinose, Inc.
Company reports third quarter 2020 XHANCE net revenue of $15.4 million New prescriptions of XHANCE increased 23% from second quarter 2020 Conference call and webcast to be held today at 8:00 a.m....
Optinose Announces Preliminary Third Quarter 2020 XHANCE Net Revenue of $15.4 Million
22 oct. 2020 07h00 HE
|
Optinose, Inc.
Preliminary XHANCE Net Revenue Growth of 78% Compared to Third Quarter 2019 and 50% Compared to Second Quarter 2020 Conference Call and Webcast to be held November 5, 2020 at 8:00 a.m. Eastern...
Optinose to Present at the Cantor Virtual Global Healthcare Conference
14 sept. 2020 08h00 HE
|
Optinose, Inc.
YARDLEY, Pa., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Announces Pricing of Public Offering of Common Stock
14 août 2020 08h04 HE
|
Optinose, Inc.
YARDLEY, Pa., Aug. 14, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, today announced the...